<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02638428</url>
  </required_header>
  <id_info>
    <org_study_id>2015-08-008</org_study_id>
    <nct_id>NCT02638428</nct_id>
  </id_info>
  <brief_title>Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy</brief_title>
  <official_title>Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of health &amp; welfare, Republic of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and feasibility of combination
      chemotherapy with target agents according to the result of targeted deep sequencing in
      pediatric patients with relapsed/refractory solid tumor or AML.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcome of pediatric cancer has been improved substantially over the past few decades, but
      the prognosis of relapsed/refractory pediatric cancer still remains poor. Advances in genomic
      technologies have improved the ability to detect diverse somatic and germline genomic
      aberrations of cancer patients, and it has been incorporated in the clinical management of
      cancer.

      Samsung Genomic Institute developed a targeted next-generation sequencing (NGS) platform,
      CancerSCAN™, which can detect clinically significant genomic aberrations of tumors. In this
      study, tumor samples of refractory/relapsed pediatric cancer patients will be tested with
      CancerSCAN™ and the patients will receive combination chemotherapy with matched
      single-targeted agent or multi-targeted receptor tyrosine kinase inhibitor according to the
      result of CancerSCAN™.

      I. Relapsed/refractory solid tumor

        -  Perform CancerSCAN™ at enrollment

        -  Conventional chemotherapy (ifosfamide, carboplatin, etoposide) with matched
           single-targeted agent (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib,
           pazopanib, ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or
           multi-targeted receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to
           the result of CancerSCAN™

      II. Relapsed/refractory AML

        -  Perform CancerSCAN™ at enrollment

        -  Conventional chemotherapy (fludarabine, cytarabine) with matched single-targeted agent
           (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib, pazopanib,
           ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or multi-targeted
           receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to the result of
           CancerSCAN™
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of event free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Event is defined as relapse, disease progression or treatment-related mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Relapsed Pediatric Solid Tumor</condition>
  <condition>Refractory Pediatric Solid Tumor</condition>
  <condition>Relapsed Pediatric AML</condition>
  <condition>Refractory Pediatric AML</condition>
  <arm_group>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional chemotherapy (Ifosfamide carboplatin etoposide for solid tumor and fludarabine cytarabine for AML) with matched single-targeted agent (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib, pazopanib, ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or multi-targeted receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to the result of CancerSCAN™</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CancerSCAN™</intervention_name>
    <description>Targeted deep sequencing</description>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <arm_group_label>Refractory/relapsed solid tumor or AML</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Under 18 years of age at initial diagnosis

          -  Patients with refractory/relapsed solid tumor or AML (Solid tumor: Stable or
             progressive disease after 1st-line treatment or relapse; AML: Persistence after 2
             cycles of induction chemotherapy or relapse)

          -  Patient with tumor sample which is adequate for targeted deep sequencing

        Exclusion Criteria:

          -  Patients who had salvage chemotherapy previously

          -  Patients with organ dysfunction as follows (creatinine elevation ≥ 3 x upper limit of
             normal (ULN), ejection fraction &lt;40%, significant arrhythmia or conduction
             disturbance)

          -  Patients who are not eligible to have scheduled treatment due to the other significant
             impaired organ function

          -  Patients whose tumor samples are not sufficient for targeted deep sequencing

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki Woong Sung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ki Woong Sung, MD, PhD</last_name>
    <phone>82-2-3410-3529</phone>
    <email>kiwoong.sung@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Woong Sung</last_name>
      <phone>82-2-3410-3529</phone>
      <email>kwsped@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Ki Woong Sung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2015</study_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Axitinib</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

